Oscar Mendez, MD
Family Medicine · Lauderdale Lakes, FLNPI 1164520243
Payments from drug & device makers
Across 183 payments — averaging $28.88 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Atricure, Inc.$1K
- Johnson & Johnson$471
- Astellas Pharma US Inc$348
- AstraZeneca$345
- Novo Nordisk$277
- Novartis$264
- plus $2K from 35 others
What the payments were for
- Food & beverage$5,11097%
- Education$1753%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Atricure, Inc. | 10 | $1,418 |
| Johnson & Johnson(3 entities) | 20 | $471 |
| Astellas Pharma US Inc | 10 | $348 |
| AstraZeneca | 16 | $345 |
| Novo Nordisk | 24 | $277 |
| Novartis | 13 | $264 |
| Pfizer | 14 | $263 |
| Heartflow, Inc. | 2 | $225 |
| Amgen(2 entities) | 6 | $175 |
| Boehringer Ingelheim | 8 | $145 |
| Lilly USA, LLC | 6 | $141 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 6 | $118 |
| Boston Scientific | 1 | $109 |
| Abiomed | 1 | $94 |
| Dexcom, Inc. | 3 | $84 |
| Cvrx, Inc. | 2 | $74 |
| Abbott | 3 | $72 |
| Merck | 4 | $66 |
| GSK | 3 | $51 |
| Medtronic | 2 | $51 |
| Bayer | 2 | $40 |
| Sunovion Pharmaceuticals Inc. | 4 | $39 |
| Phadia US Inc. | 2 | $38 |
| Hologic Sales And Service, LLC | 1 | $37 |
| Stryker | 1 | $36 |
| Global Blood Therapeutics, Inc. | 2 | $29 |
| Phathom Pharmaceuticals, Inc. | 1 | $28 |
| Otsuka America Pharmaceutical, Inc. | 1 | $27 |
| Eisai Inc. | 2 | $27 |
| Vifor Pharma, Inc. | 1 | $24 |
| Mylan Specialty L.p. | 1 | $23 |
| Ultragenyx Pharmaceutical Inc. | 1 | $23 |
| Gilead | 1 | $21 |
| Xeris Pharmaceuticals, Inc. | 1 | $18 |
| Cardiovascular Systems Inc. | 1 | $18 |
| GE HealthCare | 1 | $17 |
| Amarin Pharma, Inc. | 1 | $16 |
| Corcept Therapeutics | 1 | $13 |
| E.r. Squibb & Sons, L.L.C. | 1 | $12 |
| Grifols USA, LLC | 1 | $11 |
| Innovation Technologies Inc | 2 | $0 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$5,285 in reported general payments places this provider in the 85th percentile of 7,282 family medicine providers in Florida.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| FarxigaDapagliflozin Propanediol | 391 | $320,889 |
| JardianceEmpagliflozin | 177 | $162,100 |
| EliquisApixaban | 204 | $142,325 |
| OzempicSemaglutide | 112 | $136,065 |
| TrulicityDulaglutide | 83 | $115,994 |
| JanuviaSitagliptin Phosphate | 125 | $114,274 |
| XareltoRivaroxaban | 102 | $93,906 |
| EntrestoSacubitril/Valsartan | 84 | $73,348 |
| RybelsusSemaglutide | 43 | $71,461 |
| DescovyEmtricitabine/Tenofov Alafenam | 28 | $64,497 |
| ProliaDenosumab | 36 | $62,093 |
| TradjentaLinagliptin | 76 | $58,904 |
| MounjaroTirzepatide | 40 | $46,249 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 47 | $42,823 |
| XifaxanRifaximin | 14 | $42,752 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AstraZenecaFarxiga, Brilinta, Symbicort | $345 | $337,399430 claims |
| Boehringer IngelheimJardiance, Tradjenta | $145 | $221,005253 claims |
| Novo NordiskOzempic, Rybelsus | $277 | $207,526155 claims |
| PfizerEliquis, Nurtec Odt | $263 | $166,153227 claims |
| Lilly USA, LLCTrulicity, Mounjaro | $141 | $162,243123 claims |
| MerckJanuvia, Janumet | $66 | $123,102139 claims |
| GSKTrelegy Ellipta, Breo Ellipta, Anoro Ellipta | $51 | $94,683161 claims |
| Johnson & JohnsonXarelto | $471 | $93,906102 claims |
| NovartisEntresto | $264 | $73,34884 claims |
| GileadDescovy | $21 | $64,49728 claims |
| AmgenProlia | $175 | $62,09336 claims |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLCXifaxan | $118 | $42,75214 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 7,282 family medicine providers in Florida.
Other family medicine in Lauderdale Lakes
- Hugh ColemanDaytona Beach$115.5M
- Alexander WhiteDaytona Beach$69.7M
- Ronald SurowitzJupiter$38.3M
- Bruce RankinDeland$36.7M
- Keila HooverMiami$33.7M
- John NardandreaOcala$30.8M
- Jorge CasoMiami$22.6M
- Sharrell CooperPalm Coast$16.9M
- Christopher GallowayMelbourne$15.6M
- Dario AltamiranoHialeah$15.5M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.